First dual-specific PD-L1/PD-L2 antibody with cytotoxic killing function is designed to treat the many “immune-excluded” cancers that are resistant to existing immunotherapies. Promising early signals of activity seen as Phase 1 dose escalation proceeds.
Read moreNews
There is always something new at ImmunoGenesis. Stay on top of the latest.
Press Releases

ImmunoGenesis to Present in Innovation Track of the 2025 NeauxCancer Oncology Conference in New Orleans
March 20, 2025
Conference Innovation Track spotlights promising and emerging biotech and healthcare companies advancing the field of oncology.
Read more
ImmunoGenesis Doses First Patient in Phase 1/2 Clinical Trial of IMGS-101 in Combination With Balstilimab (anti-PD-1) and Zalifrelimab (anti-CTLA-4) in Relapsed or Refractory Advanced Prostate, Pancreatic, and HPV(-) Head & Neck Tumors
March 6, 2025
IMGS-101 is the only known reducer of solid tumor hypoxia, offering the potential to enhance the efficacy of immunotherapy.
Read moreKey Publications
Development of IMGS-001, a novel anti–PD-L1/PD-L2 dual-specific, multifunctional antibody, to treat immune-excluded tumors.
C Gagliardi, A Salameh, P Blezinger, M Hemberger, C Schweizer, J Barlow, M Curran, F Pericle. Poster presented at: Society for Immunotherapy of Cancer Annual Meeting; November 8-12, 2022; Boston, MA.
Preclinical characterization of IMGS-001, a dual-antagonist anti–PD-L1 and PD-L2 antibody with effector function, to treat patients resistant to immune checkpoint blockade.
A Salameh, C Gagliardi, P Blezinger, M Hemberger, C Schweizer, J Barlow, M Curran, F Pericle. Poster presented at: Society for Immunotherapy of Cancer Annual Meeting; November 8-12, 2022; Boston, MA.
Combination PD-1 and PD-L1 Blockade Promotes Durable Neoantigen-Specific T Cell-Mediated Immunity in Pancreatic Ductal Adenocarcinoma.
Burrack, AL, Spartz, EJ, Raynor, JF, Wang, I, Olson, M, Stromnes, IM. Cell Reports. 2019.
Genomic biomarkers in relation to PD-1 checkpoint blockade response.
Seiwert, TY, Cristescu, R, Kaufman, DR, et al. Journal of Clinical Oncology. 2018.
PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer.
Yearley, JH, Gibson, C, Yu, N, Moon, C, Murphy, E, McClanahan, T, et al. Clinical Cancer Research. 2017.
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors.
Curran, MA, Montalvo, W, Yagita, H, Allison, JP. PNAS. 2010.
Upcoming events
There are no upcoming events scheduled at this time. Sign up to receive notices about upcoming events and press releases.
Excited about what you see?
Learn more